Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.36 -0.66 (-0.79%)
Official Closing Price Updated: 7:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
The Data Shows Three Market-Jolting Forces On The Move
What we saw in the inflation data, income and spending-related reports points to a couple of big moves we need to start making now. 
Via Talk Markets
Topics Economy Stocks / Equities
Merck to Participate in the Citi 2024 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Why Is Merck Stock Trading Higher On Monday?
Merck's ZENITH trial shows Winrevair significantly lowers morbidity or mortality risk in PAH patients, building on earlier Phase 3 STELLAR results. 
Via Benzinga
Why NYSE:MRK provides a good dividend, while having solid fundamentals.
Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
From Merck & Co., Inc.
Via Business Wire
Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
From Merck & Co., Inc.
Via Business Wire
Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
From Merck & Co., Inc.
Via Business Wire
Surendralal Karsanbhai Elected to Merck Board of Directors
From Merck & Co., Inc.
Via Business Wire
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer. 
Via Benzinga
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Via The Motley Fool
Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
From Merck & Co., Inc.
Via Business Wire
NYSE:MRK appears to be flying under the radar despite its strong fundamentals.
In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
Merck's Phase 3 trial shows subcutaneous pembrolizumab is as effective as IV Keytruda for first-line NSCLC treatment, meeting key pharmacokinetic goals. 
Via Benzinga
Merck Announces First-Quarter 2025 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
From Merck & Co., Inc.
Via Business Wire
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
To gain an edge, this is what you need to know today. 
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
From Merck & Co., Inc.
Via Business Wire
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy. 
Via Benzinga
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China. 
Via Investor's Business Daily
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Stocks in these "safe" sectors are selling off as investors gravitate toward growth. 
Via The Motley Fool
Topics ETFs Stocks
Merck to Participate in the Jefferies London Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial
From Merck & Co., Inc.
Via Business Wire
Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024
From Merck & Co., Inc.
Via Business Wire
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
3 Stocks Poised for a Breakout
All 3 stocks are high on my watchlist. 
Via The Motley Fool
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS